Vorinostat

CAS 149647-78-9 1 current record 1 historicalSmall Molecule

Who holds supplier records for Vorinostat? 1 organisation holds a current record for Vorinostat: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Vorinostat: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/vorinostat

Reading the evidence

  • One current record

    One organisation holds a current DMF or CEP. A record shows a regulatory filing, not current commercial availability or a qualified source for your product.

  • No company-level GMP certificate matched

    No current EU or UK GMP certificate was matched to these organisations. That is not a negative finding; ask each candidate for its certificate and latest inspection outcome.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Vorinostat expires 18 Mar 2028. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (1)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Vorinostat. Country is the organisation's recorded country, not necessarily the manufacturing site.

  • CURIA NEW YORK INC
    Active DMF 19093 · latest filing Jan 2006
Need Vorinostat sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (1)

Organisations whose Type II DMFs for Vorinostat are no longer active. These show a past filing, not current supply.

Show all 1 historical record
  • MYLAN LABORATORIES LTD
    Inactive DMF 23409 · filed Dec 2009

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (1 listed product contain Vorinostat). The latest listed patent expires 18 Mar 2028. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), is an HDAC inhibitor used in cancer treatment. It is approved for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma.

Chemical identity

IUPAC name
N'-hydroxy-N-phenyloctanediamide
Canonical SMILES
C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
InChIKey
WAEXFXRVDQXREF-UHFFFAOYSA-N
Synonyms
Zolinza API, mk-0683, mk0683, nsc-701852, nsc-748799, nsc-759852, suberoylanilide hydroxamic acid, zolinza

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Histone Deacetylase Inhibitor
Mechanism of action
Histone Deacetylase Inhibitors

Therapeutic areas

OncologyHematology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Vorinostat?

1 organisation holds an active US FDA Type II Drug Master File or a CEP for Vorinostat: CURIA NEW YORK INC. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Vorinostat Drug Master Files are active?

CURIA NEW YORK INC (DMF 19093). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Vorinostat records mean?

1 organisation has only inactive Type II DMFs for Vorinostat. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Vorinostat?

Yes. The latest patent listed for an approved US product containing Vorinostat expires 18 Mar 2028, across 1 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Vorinostat supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Vorinostat?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.